Abstract 16347: Simplified Workflow to Improve the Precision of Non-invasive Radio-ablation of Ventricular Tachycardia Storm

Background: Stereotactic ablative radiotherapy (SAbR) is an emerging therapy for ventricular tachycardia (VT) storm, but the feasibility and outcomes guided by computational 12-lead ECG mapping and respiratory-gated radiation delivery have not been reported. Hypothesis: We hypothesized that a novel 12-lead ECG-based mapping system and respiratory-gated radiotherapy delivery may simplify the workflow and improve precision of SAbR in critically ill patients with VT storm. Methods: We enrolled patients with VT storm who were not candidates for catheter ablation. VT was induced using non-invasive stimulation and recorded on 12-lead ECGs. Computational ECG mapping was performed to localize VT exit sites. Target volumes were contoured onto an averaged free-breathing CT. Ionizing radiation (25 Gy) was delivered using a linear accelerator (Varian, Palo Alto). In patients with significant respiratory motion, radiotherapy was delivered at end-expiration, guided by ICD lead fiducials. Results: In 5 patients (age 74±6.1 years, EF 29±14%) refractory to 2±1 ablation procedures, 1.5±0.6 VT morphologies were localized on 3D models (Fig 1A) using ECG-based mapping (mapping time 1.2±0.3 min). In patients whom respiratory gating (Fig 1B) was used prospectively due to respiratory variation, the planned target volume (PTV) was smaller compared to patients who were not gated (71 ± 7 vs 153 ± 35 cc, p<0.01). These patients also had VT targets (crux or inferior LV) close to the stomach, and did not experience adverse events. ICD shocks were decreased after SAbR compared to before (0.25±0.5 vs 26±19 shocks, p<0.001) at 4.4±3.4 months follow-up. Conclusion: Non-invasive computational mapping based upon the 12-lead ECG alone simplifies radioablation workflow in critically ill VT storm patients and reduces the burden of ICD shocks. Respiratory gated radiotherapy ablation appears feasible and may help reduce target volume of therapy. Studies with longer follow-up are ongoing.

Download Full-text

Five-day accelerated partial breast irradiation (APBI) using intensity modulated radiation therapy (IMRT) in stage 0-II breast cancer: A report of 214 cases with up to 39 month follow-up.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e12508 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e12508-e12508

Author(s):

Rufus J. Mark ◽

Valerie Gorman ◽

Michal Wolski ◽

Steven McCullough

Keyword(s):

Breast Cancer ◽

Intensity Modulated Radiation Therapy ◽

Target Volume ◽

Accelerated Partial Breast Irradiation ◽

Partial Breast Irradiation ◽

Breast Irradiation ◽

Skin Reactions ◽

Cosmetic Results ◽

Non Invasive

e12508 Background: Randomized trials in stage 0-II breast cancer have proven that APBI given via HDR implant in 5 days is equivalent to whole breast irradiation (WBI) given in 5-6 weeks in regard to breast tumor local recurrence (LR). However, complications have been significant. Recently APBI using non-invasive IMRT given in 5 fractions has been shown in another randomized trial with 10 year follow-up to be equivalent to WBI in 6 weeks, with respect to LR. IMRT was superior in regard to acute effects, late effects, and cosmesis. In the randomized clinical trial of APBI IMRT, the Clinical Target Volume (CTV) was defined by the injection of individual fiducial markers bordering the surgical cavity. We have used the Biozorb fiducial system to localize the CTV for IMRT. We sought to confirm the APBI IMRT results with this simpler less labor intensive fiducial placement system. Methods: Between 2017 and 2021, 214 patients have undergone IMRT targeted to a Biozorb defined CTV with the walls of the surgical cavity sewn to the Biozorb device. Eligible patients were older than age 40, had tumor sizes < 3 cm, negative surgical margins, and negative sentinel node dissections. IMRT dose was 30 Gy given in 5 fractions. Dose Constraints were as follows : V-30 Gy < 105%, Ipsilateral Breast V-15 Gy < 50%, Ipsilateral Lung V-10 Gy < 20%, Contralateral Lung V-5 Gy < 10%, Heart V-3 Gy < 20%, Contralateral Breast Dmax < 2 Gy and Skin Dmax < 27 Gy. The Planning Target Volume (PTV) ranged from 27 to 355 cc with a median of 80 cc. PTV = CTV + 1-2 cm. Results: Follow-up ranged from 1-39 months with a median of 20 months. LR has been 0% (0/214). There have been no skin reactions or seromas. Infection has occurred in one patient (0.5%). Four (1.9%) patients developed pain around the Biozorb site. This resolved on a short courses of steroids in all cases. Cosmetic results as rated by the Surgeon, Radiation Oncologist, and Nurse, were rated excellent in 99.0% (212/214) of cases. Conclusions: Non-invasive APBI with IMRT given qd over 5 days targeted to Biozorb has resulted in LR, complications, and cosmetic results which compare favorably to invasive APBI given bid with HDR implant. At last follow-up, there have been no LR, skin reactions, or significant complications. Cosmesis has been excellent in 99.0% of patients.

Download Full-text

Five day accelerated partial breast irradiation (APBI) using stereotactic body radiation therapy (SBRT) in stage 0-II breast cancer: A report of 135 cases with up to two-year follow-up.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e12596 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e12596-e12596

Author(s):

Rufus J. Mark ◽

Valerie Gorman ◽

Steven McCullough

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Target Volume ◽

Accelerated Partial Breast Irradiation ◽

Partial Breast Irradiation ◽

Skin Reactions ◽

Cosmetic Results ◽

Non Invasive ◽

External Radiation Therapy

e12596 Background: Randomized trials in stage 0-II breast cancer have proven that APBI given via HDR implant in 5 days is equivalent to whole breast External Radiation Therapy (XRT) given in 5-6 weeks in regard to breast tumor local recurrence (LR). However, complications have been significant. Recently APBI using non-invasive IMRT given in 5 fractions has been shown in another randomized trial to be equivalent to XRT in 6 weeks, with respect to LR. IMRT was superior in regard to acute effects, late effects, and cosmesis. In the randomized clinical trial of APBI IMRT, the Clinical Target Volume (CTV) was defined by the injection of individual fiducial markers bordering the surgical cavity. At our institution, we have used the Biozorb fiducial system to localize the CTV for IMRT. We sought to confirm the APBI IMRT results with this simpler less labor intensive fiducial placement system. Methods: Between 2017 and 2020, 135 patients have undergone SBRT targeted to a Biozorb defined CTV with the walls of the surgical cavity sewn to the Biozorb device. Eligible patients were older than age 40, had tumor sizes < 3 cm, negative surgical margins, and negative sentinel node dissections. SBRT dose was 30 Gy given in 5 fractions. Dose Constraints were as follows: V-30 Gy < 105%, Ipsilateral Breast V-15 Gy < 50%, Ipsilateral Lung V-10 Gy < 20%, Contralateral Lung V-5 Gy < 10%, Heart V-3 Gy < 20%, Contralateral Breast Dmax < 2 Gy and Skin Dmax < 27 Gy. The Planning Target Volume (PTV) ranged from 27 to 355 cc with a median of 80 cc. PTV = CTV + 1-2 cm. Results: Follow-up ranged from 1-26 months with a median of 12 months. LR has been 0% (0/135). There have been no skin reactions or seromas. Infection has occurred in one patient (0.7%). Three (2.2%) patients developed pain around the Biozorb site. This resolved within 2 days on a short course of steroids in all cases. Cosmetic results as rated by the Surgeon, Radiation Oncologist, and Nurse, were rated excellent in 98.5% (133/135) of cases. Conclusions: Non-invasive APBI with SBRT given qd over 5 days targeted to Biozorb has resulted in LR, complications, and cosmetic results which compare favorably to invasive APBI given bid with HDR implant. At last follow-up, there have been no LR, skin reactions, or significant complications. Cosmesis has been excellent in 98.5% of patients.

Download Full-text

Accelerated partial breast irradiation (APBI) using intensity modulated radiation therapy (IMRT) in stage 0-II breast cancer: A preliminary report of 57 cases.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.e12068 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. e12068-e12068

Author(s):

Rufus J. Mark ◽

Valerie Gorman ◽

Steven McCullough

Keyword(s):

Breast Cancer ◽

Radiation Therapy ◽

Intensity Modulated Radiation Therapy ◽

Target Volume ◽

Accelerated Partial Breast Irradiation ◽

Partial Breast Irradiation ◽

Skin Reactions ◽

Cosmetic Results ◽

Non Invasive

e12068 Background: Randomized trials in Stage 0-II breast cancer have proven that APBI given via HDR implant in 5 days is equivalent to whole breast External Radiation Therapy (XRT) given in 5-6 weeks in regard to breast tumor local recurrence (LR). However, complications have been significant. Recently APBI using non-invasive IMRT given in 5 fractions has been shown in another randomized trial to be equivalent to XRT in 6 weeks, with respect to LR. IMRT was superior in regard to acute effects, late effects, and cosmesis. In the randomized clinical trial of APBI IMRT, the Clinical Target Volume (CTV) was defined by the injection of individual fiducial markers bordering the surgical cavity. At our institution, we have used the Biozorb fiducial system to localize the CTV for IMRT. We sought to confirm the APBI IMRT results with this simpler less labor intensive fiducial placement system. Methods: Between 2017 and 2019, 57 patients have undergone IMRT targeted to a Biozorb defined CTV with the walls of the surgical cavity sewn to the Biozorb device. Eligible patients were older than age 40, had tumor sizes ≤ 3 cm, negative surgical margins, and negative sentinel node dissections. IMRT dose was 30 Gy given in 5 fractions. Dose Constraints were as follows : V-30 Gy < 105%, Ipsilateral Breast V-15 Gy < 50%, Ipsilateral Lung V-10 Gy < 20%, Contralateral Lung V-5 Gy < 10%, Heart V-3 Gy < 20%, Contralateral Breast Dmax < 2 Gy and Skin Dmax < 27 Gy. The Planning Target Volume (PTV) ranged from 27 to 355 cc with a median of 80 cc. PTV = CTV + 1-2 cm. Results: Follow-up ranged from 1-14 months with a median of 7 months. LR has been 0% (0/57). There were no skin reactions. One patient developed pain around the Biozorb site. This resolved within 2 days on a short course of steroids. Cosmetic results as rated by the Surgeon, Radiation Oncologist, and Nurse, were rated excellent in 100% (57/57) of cases. Conclusions: Non-invasive APBI with IMRT targeted to Biozorb has resulted in LR, complications, and cosmetic results which compare favorably to invasive APBI given with HDR implant. At last follow-up, there have been no LR, skin reactions, or complications. Cosmesis has been excellent in 100% of patients.

Download Full-text

Computational ECG mapping and respiratory gating to optimize stereotactic ablative radiotherapy workflow for refractory ventricular tachycardia

Heart Rhythm O2 ◽

10.1016/j.hroo.2021.09.001 ◽

2021 ◽

Author(s):

Gordon Ho ◽

Todd F. Atwood ◽

Andrew R. Bruggeman ◽

Kevin L. Moore ◽

Elliot McVeigh ◽

...

Keyword(s):

Ventricular Tachycardia ◽

Respiratory Gating ◽

Stereotactic Ablative Radiotherapy

Download Full-text

Cardiac stereotactic ablative radiotherapy for control of refractory ventricular tachycardia: initial UK multicentre experience

Open Heart ◽

10.1136/openhrt-2021-001770 ◽

2021 ◽

Vol 8 (2) ◽

pp. e001770

Author(s):

Justin Lee ◽

Matthew Bates ◽

Ewen Shepherd ◽

Stephen Riley ◽

Michael Henshaw ◽

...

Keyword(s):

Ventricular Tachycardia ◽

High Risk ◽

Catheter Ablation ◽

Treatment Guidelines ◽

Stereotactic Ablative Radiotherapy ◽

High Risk Population ◽

Cross Sectional ◽

Non Invasive ◽

Cross Sectional Imaging ◽

First Time

BackgroundOptions for patients with ventricular tachycardia (VT) refractory to antiarrhythmic drugs and/or catheter ablation remain limited. Stereotactic radiotherapy has been described as a novel treatment option.MethodsSeven patients with recurrent refractory VT, deemed high risk for either first time or redo invasive catheter ablation, were treated across three UK centres with non-invasive cardiac stereotactic ablative radiotherapy (SABR). Prior catheter ablation data and non-invasive mapping were combined with cross-sectional imaging to generate radiotherapy plans with aim to deliver a single 25 Gy treatment. Shared planning and treatment guidelines and prospective peer review were used.ResultsAcute suppression of VT was seen in all seven patients. For five patients with at least 6 months follow-up, overall reduction in VT burden was 85%. No high-grade radiotherapy treatment-related side effects were documented. Three deaths (two early, one late) occurred due to heart failure.ConclusionsCardiac SABR showed reasonable VT suppression in a high-risk population where conventional treatment had failed.

Download Full-text

Carbon-ion pencil beam scanning for thoracic treatment – initiation report and dose metrics evaluation

Journal of Radiation Research ◽

10.1093/jrr/rrw057 ◽

2016 ◽

Vol 57 (5) ◽

pp. 576-581 ◽

Cited By ~ 3

Author(s):

Masataka Karube ◽

Shinichiro Mori ◽

Hiroshi Tsuji ◽

Naoyoshi Yamamoto ◽

Mio Nakajima ◽

...

Keyword(s):

Ion Beam ◽

Treatment Plan ◽

Respiratory Gating ◽

Free Breathing ◽

Target Volume ◽

Post Treatment ◽

Beam Scanning ◽

Carbon Ion ◽

Dose Metrics ◽

Passive Scattering

Abstract Carbon-ion beam scanning has not previously been used for moving tumor treatments. We have commenced respiratory-gated carbon-ion radiotherapy (CIRT) in the thoracic and abdominal regions under free-breathing conditions as a clinical trial. This study aimed to investigate this treatment in the lungs in comparison with passive scattering CIRT. Five patients had thoracic tumors treated with carbon-ion scanned beams using respiratory gating. We analyzed the actual treatments and calculated passive scattering treatment plans based on the same planning CT. We evaluated tumor size until 3 months post treatment and each treatment plan regarding dose delivered to 95% of the clinical target volume (CTV-D95), mean lung dose, percentage of lung receiving at least 5 Gy (RBE) (Lung-V5), Lung-V10, Lung-V20, heart maximum dose (Dmax), esophagus Dmax, cord Dmax and skin Dmax. Obvious tumor deterioration was not observed up to 3 months post treatment. The dose evaluation metrics were similar item by item between respiratory-gated scanned CIRT and passive scattering CIRT. In conclusion, scanned beam CIRT provided treatments equivalent to passive scattering CIRT for thoracic tumors. Increased sample numbers and longer-term observation are needed.

Download Full-text